CD46 measles virus receptor polymorphisms influence receptor protein expression and primary measles vaccine responses in naive australian children

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 704-710

  Clifford, Holly D ^a,b   Hayden, Catherine M ^a   Khoo, Siew Kim ^a,b   Zhang, Guicheng ^a,b   Le Souëf, Peter N ^a   Richmonda, Peter ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; MEASLES MUMPS RUBELLA VACCINE; MEMBRANE COFACTOR PROTEIN; VARICELLA ZOSTER VACCINE; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; AUSTRALIAN; CELL STIMULATION; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; ETHNIC GROUP; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; MALE; MEASLES VACCINATION; NORMAL HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE;

ANTIBODIES, VIRAL; ANTIGENS, CD46; AUSTRALIA; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MEASLES VIRUS; MEASLES-MUMPS-RUBELLA VACCINE; OCEANIC ANCESTRY GROUP; POLYMORPHISM, GENETIC; T-LYMPHOCYTES;

EID: 84860316730     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05652-11     Document Type: Article

References (34)

1. Brunell PA, Weigle K, Murphy MD, Shehab Z, Cobb E. 1983. Antibody response following measles-mumps-rubella vaccine under conditions of customary use. JAMA 250:1409-1412. (Pubitemid 13002547)
2. Centers for Disease Control and Prevention. 2009. Global measles mortality, 2000-2008. Wkly. Epidemiol. Rec. 58:1321-1326.
3. Clifford HD, et al. 2011. SLAM and DC-SIGN measles receptor polymorphisms and their impact on antibody and cytokine responses to measles vaccine. Vaccine 29:5407-5413.
4. Crimeen-Irwin B, et al. 2003. Ligand binding determines whether CD46 is internalized by clathrin-coated pits or macropinocytosis. J. Biol. Chem. 278:46927-46937. (Pubitemid 37452275)
5. Dhiman N, Jacobson RM, Poland GA. 2004. Measles virus receptors: SLAM and CD46. Rev. Med. Virol. 14:217-229. (Pubitemid 38879814)
6. Dhiman N, et al. 2007. Associations between measles vaccine immunity and single-nucleotide polymorphisms in cytokine and cytokine receptor genes. J. Infect. Dis. 195:21-29. (Pubitemid 44958223)
7. Dhiman N, et al. 2007. Variations in measles vaccine-specific humoral immunity by polymorphisms in SLAM and CD46 measles virus receptors. J. Allergy Clin. Immunol. 120:666-672. (Pubitemid 47320741)
8. Dhiman N, et al. 2008. Associations between SNPs in Toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: Preliminary results. Vaccine 26:1731-1736.
9. Erlenhofer C, Duprex WP, Rima BK, Ter Meulen V, Schneider-Schaulies J. 2002. Analysis of receptor (CD46, CD150) usage by measles virus. J. Gen. Virol. 83:1431-1436. (Pubitemid 34591337)
10. Esolen LM, Ward BJ, Moench TR, Griffin DE. 1993. Infection of monocytes during measles. J. Infect. Dis. 168:47-52. (Pubitemid 23178728)
11. Gans HA, et al. 1999. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J. Immunol. 162:5569-5575. (Pubitemid 29307170)
12. Huang Z, Dry I, Webster D, Strugnell R, Wesselingh S. 2001. Plantderived measles virus hemagglutinin protein induces neutralizing antibodies in mice. Vaccine 19(15-16):2163-2171. (Pubitemid 32178367)
13. Jacobson RM, Poland GA. 2004. The genetic basis for measles vaccine failure. Acta Paediatr. Suppl. 93:43-46.
14. Katayama Y, Hirano A, Wong TC. 2000. Human receptor for measles virus (CD46) enhances nitric oxide production and restricts virus replication in mouse macrophages by modulating production of alpha/beta interferon. J. Virol. 74:1252-1257. (Pubitemid 30044074)
15. Liszewski MK, Post TW, Atkinson JP. 1991. Membrane cofactor protein (MCP or CD46): Newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9:431-455.
16. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215.
17. Naniche D, et al. 1993. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J. Virol. 67:6025-6032. (Pubitemid 23277513)
18. Newport MJ, et al. 2004. Genetic regulation of immune responses to vaccines in early life. Genes Immun. 5:122-129. (Pubitemid 38967641)
19. Ovsyannikova IG, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. 2006. Human leukocyte antigen haplotypes in the genetic control of immune response to measles-mumps-rubella vaccine. J. Infect. Dis. 193: 655-663. (Pubitemid 43273493)
20. Pebody RG, et al. 2002. Immunogenicity of second dose measlesmumps-rubella (MMR) vaccine and implications for serosurveillance. Vaccine 20(7-8):1134-1140. (Pubitemid 34135949)
21. Perneger TV. 1998. What's wrong with Bonferroni adjustments. BMJ 316:1236-1238. (Pubitemid 28171344)
22. Poland GA, Jacobson RM. 1998. The genetic basis for variation in antibody response to vaccines. Curr. Opin. Pediatr. 10:208-215. (Pubitemid 28256723)
23. Rivailler P, Trescol-Biemont MC, Gimenez C, Rabourdin-Combe C, Horvat B. 1998. Enhanced MHC class II-restricted presentation of measles virus (MV) hemagglutinin in transgenic mice expressing human MV receptor CD46. Eur. J. Immunol. 28:1301-1314.
24. Rowe J, et al. 2001. Heterogeneity in diphtheria-tetanus-acellular pertussis vaccine-specific cellular immunity during infancy: Relationship to variations in the kinetics of postnatal maturation of systemic Th1 function. J. Infect. Dis. 184:80-88. (Pubitemid 32568504)
25. Rowe J, et al. 2005. Th2-associated local reactions to the acellular diphtheria-tetanus-pertussis vaccine in 4-to 6-year-old children. Infect. Immun. 73:8130-8135. (Pubitemid 41740300)
26. Sakurai F, Akitomo K, Kawabata K, Hayakawa T, Mizuguchi H. 2007. Downregulation of human CD46 by adenovirus serotype 35 vectors. Gene Ther. 14:912-919. (Pubitemid 46780074)
27. Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989. (Pubitemid 32289743)
28. Tan PL, Jacobson RM, Poland GA, Jacobsen SJ, Pankratz VS. 2001. Twin studies of immunogenicity-determining the genetic contribution to vaccine failure. Vaccine 19:2434-2439. (Pubitemid 32234254)
29. Upham JW, et al. 2002. Development of interleukin-12-producing capacity throughout childhood. Infect. Immun. 70:6583-6588. (Pubitemid 35387884)
30. Varior-Krishnan G, Trescol-Biemont MC, Naniche D, Rabourdin-Combe C, Gerlier D. 1994. Glycosyl-phosphatidylinositol-anchored and transmembrane forms of CD46 display similar measles virus receptor properties: Virus binding, fusion, and replication; down-regulation by hemagglutinin; and virus uptake and endocytosis for antigen presentation by major histocompatibility complex class II molecules. J. Virol. 68:7891-7899.
31. Wickens M, Anderson P, Jackson RJ. 1997. Life and death in the cytoplasm: Messages from the 3= end. Curr. Opin. Genet. Dev. 7:220-232. (Pubitemid 27206761)
32. World Health Organization. 2002. The World Health Report: Reducing risks, promoting healthy life. World Health Organization, Geneva, Switzerland.
33. Yant S, Hirano A, Wong TC. 1997. Identification of a cytoplasmic Tyr-X-X-Leu motif essential for down regulation of the human cell receptor CD46 in persistent measles virus infection. J. Virol. 71:766-770. (Pubitemid 26412356)
34. Yerkovich ST, et al. 2007. Assessment of the potency and potential immunomodulatory effects of the measles mumps rubella and varicella vaccine in infants. Vaccine 25:1764-1770. (Pubitemid 46176329)